banner
 

Recent News

Jeffrey Weber, M.D., Ph.D., joins ImmuRx Scientific Advisory Board (06/11)
NIH Awards $2,776,000 for Lead Compound Development (1/15/11)
NIH Awards $537,000 SBIR for Combination Therapies (03/10)
ImmuRx Raises $100,000 Seed Funding from Allyon Capital (12/09)
Susan Dana Jones, Ph.D., Joins ImmuRx as Vice President of Research & Development (10/09)
John G. McHutchison, MD, brings Hep C expertise to Scientific Advisory Board (9/09)
NIH Awards $577,000 SBIR for Treatment of Tuberculosis (9/09)
ImmuRx Raises Additional Seed Funding from Angeli (6/09)
ImmuRx Raises $250,000 Seed Funding from Allyon Capital (6/09)
NIH Awards $329,000 SBIR for hCD40 Evaluation (2/09)
New Laboratory Space at Dartmouth Regional Technology Center (2/09)
Key Patent Issued with Broad Claims (06/08)
3M Agreement Strengthens IP Portfolio (PR 6/08)
Funding by NH Innovation Research Center (1/08)
Kedl Lab Receives National Respiratory BioDefense Research Lab Award (9/07)
 

 
Jeffrey Weber, M.D., Ph.D., joins ImmuRx Scientific Advisory Board (June 2011)

June 2011

Jeffrey Weber, M.D, Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center, has joined the ImmuRx Scientific Advisory Board. Dr. Weber’s clinical interests are in the immunotherapy of melanoma and other malignancies, with a focus on vaccines, adoptive immunotherapy, dendritic cell therapy and the use of immune modulating antibodies. Dr. Weber has an extensive history of conducting translational and investigator-initiated clinical trials.

 

 
NIH Awards $2,776,000 for Lead Compound Development (1/15/11)

January 2011

ImmuRx received an NIH Phase 2 SBIR award of $2,776,000 to develop our lead CD40 compound. The award will cover humanization of a CD40 antibody, primate studies and clinical trial design. This will advance the platform development for treatment of cancers and chronic infectious diseases.

 

 
NIH Awards $537,000 SBIR for Combination Therapies (03/10)

March 2010

ImmuRx has received a $537,000 SBIR award from NIH to study the benefits of combining the ImmuRx adjuvant platform with anti-angiogenic agents and/or cytoreductive chemotherapy. This may expand the application of the ImmuRx platform to a variety of hard-to-treat tumor states.

 

 
ImmuRx Raises $100,000 Seed Funding from Allyon Capital (12/09)

December 24, 2009

ImmuRx Inc., has received an incremental $100,000 investment from Allyon Solutions, LLC. The funding is a follow on investment to the $250,000 that Allyon invested in June of 2009 and will be used to continue the development of ImmuRx’s lead compound, hCD40, and expand its patent portfolio.

“ImmuRx is pleased with the desire of Allyon to make a follow on investment. The partnership between Allyon and ImmuRx has worked well during 2009 and we are pleased with the clear signal of support the additional funding implies. Allyon continues to be a constructive resource for us, not just for their capital investment but for their business insight, strategic advice, and financial solutions“ said ImmuRx CEO David DeLucia.

Allyon Solutions is a Hanover, New Hampshire, based investment firm with integrated operations in growth capital and finance. Allyon invests in new technologies, backing entrepreneurs who have developed proprietary or patented technologies with start-up capital. Where appropriate, Allyon works closely with its portfolio CEOs to provide management support, strategic advice, marketing guidance, and fundraising assistance. Allyon often helps its clients find the best possible funding sources during this critical period. Allyon's other subsidiaries including Allyon Financial Advisors, LLC.

 

Susan Dana Jones, Ph.D., Joins ImmuRx as Vice President of Research & Development  (10/09)

Susan Dana Jones, Ph.D., has more than 20 years of discovery, product development, and strategic planning experience in biotechnology. She co-founded two biotechnology companies and has managed discovery and product development programs in multiple organizations and for multiple disease areas. Dr. Jones received her Bachelor's degree from Harvard University, her Ph.D. from the University of California, San Francisco, and performed post-doctoral research at the Dana-Farber Cancer Institute of Harvard Medical School.

“We are pleased to have Susan join our team. She brings strong product development experience to the team as we prepare to move towards the clinic,” said David DeLucia, CEO.

 

John G. McHutchison, MD, brings Hep C expertise to Scientific Advisory Board (9/09)

John G. McHutchison, MD, Associate Director, Duke Clinical Research Institute and Director of GI / Hepatology Research, joined the ImmuRx Scientific Advisory Board.

“John brings an excellent clinical perspective on Hepatitis C to our efforts. He is very active in the clinical development of the newest Hep C treatments. We are very pleased to have John join our team.” said David DeLucia, CEO.

 

NIH Awards $577,000 SBIR for Treatment of Tuberculosis (09/09)

ImmuRx has been awarded a $577,000 SBIR award from NIH to study the application of its adjuvant platform to the treatment of tuberculosis. This award will support the extension of the ImmuRx platform from treating cancer to treating chronic infectious diseases such hepatitis C as well as TB.

 

ImmuRx Raises Additional Seed Funding from Angeli Parvi (6/09)

ImmuRx Inc. has raised seed funding from Angeli Parvi. This funding will be added to the $250,000 raised from Allyon Capital Partners.

 

ImmuRx Raises $250,000 Seed Funding from Allyon Capital (6/09)

June 16, 2009

ImmuRx Inc., has raised $250,000 of seed funding from Allyon Capital Partners. The seed funding will be added to the $329,000 NIH SBIR grant that ImmuRx was awarded in April to develop their lead compound, hCD40, and expand their patent portfolio.

“Allyon has been an invaluable resource for us, not just for their capital investment but for their business insight, strategic advice, and financial solutions” said ImmuRx CEO David DeLucia.

Allyon Solutions is a Hanover, New Hampshire, based investment firm with integrated operations in growth capital, finance, and real estate. Through its subsidiary, Allyon Capital Partners, LLC, Allyon invests in new technologies, backing entrepreneurs who have developed proprietary or patented technologies with start-up capital. Where appropriate, Allyon works closely with its portfolio CEOs to provide management support, strategic advice, marketing guidance, and fundraising assistance. Allyon often helps its clients find the best possible funding sources during this critical period. Allyon's other subsidiaries include Allyon Financial Advisors, LLC, and Allyon Real Estate Solutions, LLC.

 

NIH Awards $329,000 SBIR for hCD40 Evaluation (02/09)

ImmuRx has been awarded a $329,000 SBIR award from NIH for the evaluation of hCD40 agonists. Start date April 1, 2009. This award will support the development of an hCD40 component for the ImmuRx platform.

 

 
New Laboratory Space at Dartmouth Regional Technology Center (02/09)

ImmuRx leases lab space at the Dartmouth Regional Technology Center, a 22,000 square foot mixed-used technology incubator facility, with wet lab incubator space and with access to common, shared infrastructure. The mission of the DRTC is to support the successful launching of new technology companies.

 

 
Key Patent Issued with Broad Claims (06/08)

June 17, 2008

The U.S. Patent Office allowed broad claims for CD40 – TLR combinations in U.S. Patent 7,387,271, “Immunostimulatory Combinations”. This provides protection for the broad adjuvant platform discovered by ImmuRx scientists who demonstrated that stimulating both TLR and CD40 receptors caused synergistic effects.

 

 
3M Agreement (Press Release)

ImmuRx Announces Agreement with 3M for Safer, More Effective Treatment of Cancer

Agreement Strengthens ImmuRx’s Leading Adjuvant Platform

LEBANON, N.H. , DATE, June 4, 2008.  ImmuRx Inc. today announced that they have entered into an agreement with 3M to advance the development of safer and more effective treatments for a wide variety of cancers and chronic infectious diseases.

Under the agreement, ImmuRx has acquired exclusive intellectual property rights to combinations of various toll-like receptor (TLR) and CD40 agonists, which are molecules involved in stimulating both short and long term immunity. Researchers at 3M and ImmuRx have shown that the combinations are a powerful new way to stimulate the immune system.  3M will take an equity position in ImmuRx.

“The vaccine adjuvants from 3M strengthen our leading intellectual property portfolio around TLR-CD40 combinations. We are pleased to add this intellectual property to our growing portfolio.” says David DeLucia, CEO of ImmuRx. “The ImmuRx immunotherapy platform has been shown to activate over 10x more antigen-specific T cells and to deliver greater therapeutic benefit than any TLR or CD40 agonist alone. We’ve shown this in animal models of solid tumors and hematapoietic tumors as well as chronic viral and bacterial infections. It is a remarkable immunotherapy platform that is overwhelmingly effective even in severely immuno-compromised hosts,” says Randolph Noelle, co-founder and CSO of ImmuRx, Professor and Chair of Immunology at the Dartmouth Medical School and Director of the Cancer Immunotherapy Program at the Dartmouth-Hitchcock Medical Center.

“We are pleased to participate in this promising opportunity to bring our discoveries to patients in need,” said Sharon K. Grosh, Director, Strategic Intellectual Asset Management, 3M. “ImmuRx's immunotherapy platform has the potential to prevent and treat a number of important diseases and is a good complement to our TLR vaccine adjuvant business," added Dr. Steven Wick, Technical Director, 3M Drug Delivery Systems.

About 3M Drug Delivery Systems
3M Drug Delivery Systems develops, licenses, and manufactures a wide range of drug formulation and delivery technologies for transdermal patch, aerosol inhalation, and microneedle products, and has recently began offering resiquimod and other TLR 7 and/or 8 agonists for use as vaccine adjuvants.

About ImmuRx Inc.
ImmuRx Inc. is a biopharmaceutical company developing an adjuvant platform that stimulates the immune system to fight a wide variety of cancers and chronic infections. ImmuRx has developed the leading intellectual property estate for combinations of stimulants that trigger both the innate and adaptive halves of the immune system, producing more powerful and safer treatments. ImmuRx is based in Lebanon, NH.
 

Contact:
David DeLucia, CEO
ImmuRx Inc.
802-649-8109 DeLucia@ImmuRx.com

 

 
Funding by NH Innovation Research Center (1/08)

The New Hampshire Innovation Research Center awarded ImmuRx and Dartmouth College $125,000 to advance ImmuRx’s proprietary treatment for cancer and infectious disease.

 

 
Kedl Lab Receives National Respiratory BioDefense Research Lab Award (9/07)

The laboratory of Dr. Ross Kedl at the University of Colorado has received a multi-year, multiple PI, National Respiratory BioDefense Research Lab award from the Department of Defense for the study of novel adjuvants against infectious disease. Dr. Kedl is a co-founder of ImmuRx.

 

 

 


       
   
    © Copyright 2008 ImmuRx.com All Rights Reserved Site Map Site Designed By: Kristy Ford Creative